

Special Issue

The Role of Sphingolipids in Cancer Progression

Message from the Guest Editor

Our understanding of the role of sphingolipids in the progression of cancer is ever-evolving. With the advent of techniques such as spatial transcriptomics, proteomics and metabolomics, we will undoubtedly discover novel roles for well-characterized sphingolipids, such as sphingosine-1-phosphate and ceramide, and the enzymes that catalyze their generation. However, it is also likely that less studied sphingolipids and sphingolipid metabolizing enzymes will be increasingly recognized as important modulators of cancer progression. This Special Issue is designed to highlight methods and strategies that reveal these rare sphingolipids/enzymes and their role(s) in the development, progression and metastasis of cancer. A better understanding of how sphingolipids influence tumor development will hopefully lead to the identification of novel sphingolipid targets and novel therapeutic strategies to block tumorigenesis and/or tumor progression.

Guest Editor

Dr. Jeremy Hengst

Department of Pediatrics, Penn State College of Medicine, Hershey, PA, USA

Deadline for manuscript submissions

30 October 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/258421

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)